Last updated: August 1, 2026
AmBisome, the branded liposomal formulation of amphotericin B, remains a key hospital antifungal and an important treatment for visceral leishmaniasis and cryptococcal meningitis. Its clinical value is strongest where rapid fungicidal activity and reduced renal toxicity are required. Commercial growth is constrained by generic competition, tender-based procurement, limited use outside hospitals, and the availability of cheaper conventional amphotericin B or newer oral antifungals.
AmBisome has no meaningful late-stage branded pipeline. Current clinical activity centers on treatment optimization, shorter cryptococcal meningitis regimens, neglected tropical disease programs, pediatric use, pharmacoeconomic studies, and deployment in low- and middle-income countries.
What is AmBisome and how is it used?
AmBisome is liposomal amphotericin B, an intravenous polyene antifungal marketed by Gilead Sciences. The product encapsulates amphotericin B in unilamellar liposomes composed principally of hydrogenated soy phosphatidylcholine, cholesterol and distearoyl phosphatidylglycerol.
The liposomal delivery system changes amphotericin B distribution and reduces exposure of the kidneys relative to conventional amphotericin B deoxycholate. The product is administered intravenously and is not interchangeable with conventional amphotericin B on a milligram-for-milligram basis.
Main FDA-approved indications
The U.S. label includes:
- Empirical treatment of presumed fungal infections in febrile, neutropenic patients.
- Treatment of cryptococcal meningitis in HIV-infected patients.
- Treatment of visceral leishmaniasis.
- Treatment of systemic fungal infections caused by susceptible organisms, including species of Candida, Aspergillus, Cryptococcus and certain molds, according to the labeled use and clinical context.
AmBisome is also used off label for mucormycosis, disseminated fungal infections, neonatal candidiasis and other invasive mycoses when clinicians require amphotericin B activity with a better renal safety profile than the conventional formulation.
The product is not approved as an oral treatment. Its intravenous administration, infusion monitoring and hospital-use profile limit outpatient utilization.
What is the current clinical-trial status of AmBisome?
AmBisome has moved from registration-focused development to post-approval clinical optimization. No major Phase 3 program is required to establish the product's original indications. New trials generally evaluate dose, treatment duration, combination therapy, population-specific use or access in endemic countries.
Cryptococcal meningitis trials
The most commercially and clinically relevant modern evidence concerns shorter induction therapy for cryptococcal meningitis.
The ACTA trial compared shorter antifungal induction regimens in adults with HIV-associated cryptococcal meningitis in sub-Saharan Africa. A regimen containing one week of amphotericin B plus flucytosine was noninferior to longer amphotericin-based regimens for mortality at 10 weeks, while reducing treatment burden and toxicity. The trial included amphotericin B formulations used in routine care, including liposomal amphotericin B in relevant treatment arms (Molloy et al., 2018).
The AMBITION-cm trial evaluated a single high dose of liposomal amphotericin B, 10 mg/kg, combined with oral flucytosine and fluconazole. The regimen was noninferior to the standard seven-day amphotericin B regimen and was associated with fewer severe adverse events and substantially less amphotericin exposure (Jarvis et al., 2022).
These results changed the clinical positioning of liposomal amphotericin B in cryptococcal meningitis. The product may now be used as a high-dose, single-infusion induction component in settings where flucytosine and close follow-up are available. The approach also reduces infusion days, laboratory monitoring and inpatient resource use.
Visceral leishmaniasis trials
AmBisome is a central treatment for visceral leishmaniasis. Clinical research has focused on:
- Single-dose and shortened-course treatment.
- Regional dosing differences in East Africa and the Indian subcontinent.
- Combination regimens with miltefosine, paromomycin or antimonials.
- Pediatric treatment.
- Relapse prevention in immunocompromised patients.
- Field delivery through public-health and donor-funded programs.
The World Health Organization recommends liposomal amphotericin B in several visceral leishmaniasis treatment settings. Dosing varies by geography, immune status and disease severity. In East Africa, cumulative doses are often higher than in the Indian subcontinent because of differences in parasite species, patient characteristics and treatment response (World Health Organization, 2022).
Mucormycosis and invasive mold infections
AmBisome is widely used for mucormycosis because of its activity against many Mucorales species and its established use in severely ill patients. Clinical evidence is primarily observational, retrospective or based on comparative antifungal studies rather than a dedicated registration trial.
The product is also used when voriconazole is unsuitable because of suspected mucormycosis, drug interactions, resistance or the need for broad initial mold coverage. Posaconazole and isavuconazole are important step-down or alternative therapies, but they do not eliminate the role of liposomal amphotericin B in severe disease.
Recent clinical-development direction
The clinical-development opportunity for AmBisome is concentrated in four areas:
| Area |
Development objective |
Commercial effect |
| Cryptococcal meningitis |
Single-dose or short-course induction |
Reduces hospital and infusion burden while preserving demand for high-dose product |
| Visceral leishmaniasis |
Regional and combination regimens |
Supports public-sector volume, often at tender prices |
| Pediatric and neonatal use |
Safer dosing in vulnerable patients |
Supports institutional adoption but has limited branded pricing power |
| Resistant or difficult invasive mycoses |
Salvage and empiric use |
Preserves specialist demand despite generic competition |
What is the FDA regulatory status of AmBisome?
AmBisome is an FDA-approved prescription product under NDA 050740. Gilead Sciences is the reference-product sponsor listed in FDA regulatory materials for the branded product (U.S. Food and Drug Administration, Drugs@FDA).
The key regulatory attributes are:
| Regulatory item |
Status |
| Active ingredient |
Liposomal amphotericin B |
| Dosage form |
Intravenous injection for infusion |
| Reference product |
AmBisome |
| U.S. application |
NDA 050740 |
| FDA pathway |
New drug application |
| Pediatric use |
Label-dependent, with substantial clinical use in children |
| Biosimilar pathway |
Not applicable |
| Generic pathway |
ANDA pathway is applicable |
| Controlled substance status |
Not controlled |
AmBisome is not a biologic, so biosimilar substitution rules do not apply. Competition enters through abbreviated new drug applications, not 351(k) biosimilar applications.
What is the Orange Book status of AmBisome?
AmBisome is an FDA-listed small-molecule drug product. The relevant competitive question is whether enforceable patents or regulatory exclusivities remain listed for the reference product.
The original formulation and delivery patents were filed decades ago. Their principal U.S. patent terms have expired or are no longer the primary barrier to generic entry. AmBisome therefore has limited protection from an active, long-duration patent estate compared with recently launched antifungal products.
The main barriers are practical rather than patent-based:
- Complex liposome manufacture.
- Control of particle-size distribution and encapsulation.
- Sterility and pyrogen control.
- Physical stability during storage.
- Demonstration of pharmaceutical equivalence.
- Scale-up of sterile injectable production.
- Hospital formulary and procurement qualification.
These factors can delay generic entry even when basic formulation patents have expired. They do not provide the same legal exclusivity as an unexpired composition or formulation patent.
What patents protect AmBisome?
AmBisome's historic protection was based on liposomal amphotericin B composition, lipid selection, particle characteristics, manufacturing processes and pharmaceutical formulations. The most commercially important patent families were associated with NeXstar Pharmaceuticals and later Gilead Sciences.
The relevant patent position has weakened substantially because the product was developed in the 1980s and 1990s. Standard U.S. patent terms for those families generally expired by the 2010s, subject to individual patent-term adjustments and extensions.
Patent strength assessment
| Patent category |
Current barrier level |
Assessment |
| Amphotericin B active ingredient |
Low |
Old, established molecule |
| Liposomal composition |
Low to moderate |
Historic patents largely aged or expired |
| Manufacturing process |
Moderate |
Process know-how can remain difficult to reproduce |
| Sterile injectable production |
Moderate |
Regulatory and technical barrier |
| Method of use |
Low to moderate |
Some uses may be covered by later patents, but broad clinical use is established |
| Brand and trade dress |
Moderate |
Supports commercial differentiation but does not block generic approval |
| Data exclusivity |
Low |
Original U.S. approval is long past standard exclusivity periods |
The strongest residual protection is manufacturing know-how, not broad product exclusivity. Generic applicants must reproduce a complex injectable liposome product with consistent quality, but the reference sponsor does not appear to have a modern patent thicket comparable with those surrounding newer antifungal delivery systems.
When does AmBisome lose exclusivity?
AmBisome's core U.S. regulatory and patent exclusivity expired long ago. The product's commercial exclusivity is now based on brand recognition, clinical familiarity, supply reliability and procurement relationships.
The relevant timeline is:
| Milestone |
Approximate timing |
| Liposomal amphotericin B development and early clinical use |
1980s-1990s |
| U.S. approval of AmBisome |
1997 |
| Original small-molecule regulatory exclusivity |
Expired |
| Early formulation patent terms |
Largely expired during the 2010s |
| Current market position |
Branded product competing with generic or alternative suppliers |
No biosimilar exclusivity issue applies. Any remaining commercial protection comes from manufacturing complexity and buyer preference.
Which companies are challenging AmBisome?
Competition comes from generic manufacturers, conventional amphotericin B suppliers and alternative antifungal developers.
Generic and formulation competitors
Potential and actual competitors include manufacturers with sterile injectable and complex formulation capabilities, such as:
- Cipla.
- Sun Pharmaceutical Industries.
- Dr. Reddy's Laboratories.
- Fresenius Kabi.
- Mylan and Viatris-related injectable operations.
- Regional manufacturers in India, China, Latin America and other tender markets.
The exact competitive set differs by country because regulatory approvals, procurement tenders and local manufacturing requirements vary.
Conventional amphotericin B deoxycholate remains a lower-cost competitor in settings where renal monitoring is available and price is the primary selection factor. Liposomal amphotericin B is preferred when nephrotoxicity, infusion reactions or cumulative exposure are major concerns.
Alternative antifungal competitors
AmBisome competes clinically with:
- Liposomal and non-liposomal amphotericin B products.
- Voriconazole for invasive aspergillosis.
- Isavuconazole for invasive aspergillosis and mucormycosis.
- Posaconazole for mold infections and prophylaxis.
- Echinocandins for invasive candidiasis.
- Fluconazole for susceptible Candida and cryptococcal consolidation or maintenance treatment.
- Miltefosine and paromomycin in selected leishmaniasis programs.
These drugs do not all compete on a direct molecule-for-molecule basis. Their effect on AmBisome depends on pathogen, disease severity, renal status, drug interactions, route of administration and public-sector treatment guidelines.
What generic entry risks exist for AmBisome?
Generic entry risk is high in principle and moderate in commercial execution.
Legal risk
The core product is old and the original patent estate is substantially aged. A Paragraph IV challenge would be relevant only if a generic applicant confronted a listed, unexpired patent in the Orange Book. The commercial importance of such a challenge is lower than for a recently launched branded drug because generic development can proceed against a relatively mature product with established clinical use.
Technical risk
The principal difficulty is pharmaceutical equivalence. A generic liposomal amphotericin B product must control:
- Liposome size and size distribution.
- Amphotericin B loading and leakage.
- Lipid composition.
- Free amphotericin B content.
- Sterility and endotoxin levels.
- Reconstitution behavior.
- Infusion performance.
- Stability and shelf life.
Small changes in liposome characteristics can affect tissue distribution and toxicity. This creates a higher development burden than for a conventional immediate-release tablet.
Commercial risk
Even after approval, a generic must secure hospital contracts, demonstrate reliable supply and compete in tenders. AmBisome can retain share in tertiary hospitals and difficult-to-treat infections, while generics gain share in public procurement and price-sensitive markets.
What is the market size and outlook for AmBisome?
Public companies do not consistently report AmBisome revenue as a standalone line item. Market-research estimates for liposomal amphotericin B vary because they use different geographic scopes, pricing assumptions and definitions of the product segment.
The market is best analyzed through demand drivers rather than a single headline figure.
Demand drivers
Demand is supported by:
- Growth in invasive fungal infections among cancer and transplant patients.
- Increased recognition of mucormycosis.
- HIV-associated cryptococcal disease in high-burden countries.
- Visceral leishmaniasis treatment programs.
- Preference for reduced nephrotoxicity over conventional amphotericin B.
- Use in critically ill patients requiring broad initial antifungal coverage.
Demand is constrained by:
- Generic and tender price erosion.
- Oral azoles for step-down treatment.
- Echinocandins in candidiasis.
- Limited diagnosis of invasive fungal infections.
- Hospital budget pressure.
- Manufacturing and supply interruptions.
- Lower use in outpatient settings because intravenous administration is required.
Market projection framework
A reasonable base case for 2024-2030 is low-single-digit annual growth in global liposomal amphotericin B volume, offset by flat-to-declining average selling prices. Branded AmBisome revenue is likely to grow more slowly than total category volume because generic penetration and public-sector tendering reduce price and share.
| Scenario, 2024-2030 |
Volume trend |
Price trend |
Branded AmBisome implication |
| Bear case |
Flat to low growth |
High erosion |
Revenue declines |
| Base case |
Low-single-digit growth |
Low-to-moderate erosion |
Revenue broadly stable to modestly higher |
| Bull case |
Mid-single-digit growth |
Limited erosion |
Revenue grows through demand and premium retention |
The strongest volume opportunity is in cryptococcal meningitis and visceral leishmaniasis programs. The strongest value opportunity is in high-income hospital markets treating mucormycosis, invasive mold infections and severe candidiasis. These segments have different economics: donor-funded and government procurement produces volume at low prices, while hospital markets produce higher revenue per vial.
How does AmBisome compare with conventional amphotericin B?
| Attribute |
AmBisome |
Amphotericin B deoxycholate |
| Formulation |
Liposomal |
Conventional suspension |
| Route |
Intravenous |
Intravenous |
| Renal toxicity |
Lower relative risk |
Higher risk |
| Infusion reactions |
Generally reduced, but still possible |
More frequent |
| Acquisition cost |
High |
Low |
| Monitoring burden |
Lower than conventional formulation |
Higher |
| Use in resource-limited settings |
Increasing where donor or government funding exists |
Retained where price dominates |
| Manufacturing complexity |
High |
Lower |
| Generic substitution |
Technically difficult |
More straightforward |
AmBisome has a clinically meaningful safety advantage but a weaker cost position. Pharmacoeconomic value is highest when reduced renal injury, shorter hospitalization or lower monitoring costs offset the acquisition-price premium.
What litigation and settlement agreements affect AmBisome?
AmBisome is not associated with a current, high-profile patent litigation cycle comparable with newer blockbuster drugs. The product's principal patent barriers are old, and current competitive disputes are more likely to involve product quality, regulatory approval, procurement, supply, trademarks or manufacturing than a fresh composition-of-matter challenge.
No major active U.S. settlement agreement materially reshapes the publicly visible AmBisome launch timeline. Generic launch timing is therefore driven mainly by regulatory approval, manufacturing readiness and market access.
What generic launch scenarios are most likely?
Scenario 1: Tender-led generic substitution
A generic manufacturer enters a public-sector market with a lower price and wins hospital or government contracts. AmBisome retains share in specialist centers and countries where the reference product is preferred.
Scenario 2: Regional multi-supplier competition
Several suppliers obtain approvals in India, Latin America, Asia or Africa. Price competition increases, but supply reliability becomes a differentiator. The branded product remains relevant where procurement agencies require established clinical and manufacturing records.
Scenario 3: Limited generic penetration
Technical complexity, low prices and sterile manufacturing requirements limit the number of approved suppliers. AmBisome retains a substantial share despite the absence of broad patent exclusivity.
The third scenario is more plausible in markets with stringent injectable-product requirements and lower volumes. The first two are more likely in large public-health procurement markets.
What geographic markets matter most for AmBisome?
North America and Western Europe
These markets generate higher revenue per treatment course but have strong generic, formulary and pharmacoeconomic pressure. Use is concentrated in tertiary hospitals, oncology, transplant, intensive care and infectious disease services.
India and South Asia
India is important for both visceral leishmaniasis treatment and generic manufacturing. Local procurement and lower prices can increase patient access while reducing branded revenue.
East Africa
East Africa is clinically important because of visceral leishmaniasis and cryptococcal meningitis. Treatment access depends heavily on international procurement, donor funding, supply logistics and availability of flucytosine.
Latin America
Demand is supported by endemic fungal disease, leishmaniasis and hospital treatment of severe mycoses. Country-specific registration and public procurement determine supplier share.
China and other Asian markets
Hospital antifungal demand is expanding, but local manufacturers and public procurement exert strong pricing pressure. Regulatory acceptance of complex generic liposomal products is the principal market-access issue.
Key Takeaways
- AmBisome is liposomal amphotericin B, an established intravenous antifungal with lower renal toxicity than conventional amphotericin B.
- The strongest current clinical evidence supports shorter and single-dose induction strategies for cryptococcal meningitis.
- Visceral leishmaniasis remains a major public-health use, with dosing and demand varying by region.
- AmBisome has no active biosimilar issue because it is a small-molecule drug.
- Core patent and regulatory exclusivity expired years ago; manufacturing complexity is the main residual barrier.
- Generic entry risk is high over the long term, but complex liposome manufacturing can limit the number of successful suppliers.
- Category volume should grow modestly through 2030, while branded revenue faces price erosion.
- High-value demand is concentrated in severe invasive fungal infections; high-volume demand is concentrated in public-health and neglected-disease programs.
- No major current patent litigation or settlement is expected to create a new branded exclusivity period.
FAQs About AmBisome Clinical Trials and Market Outlook
Is AmBisome still considered a first-line treatment for cryptococcal meningitis?
Yes. Liposomal amphotericin B remains a core induction treatment, usually combined with flucytosine and fluconazole. High-dose single-infusion regimens are supported by modern clinical-trial evidence in HIV-associated cryptococcal meningitis.
Can AmBisome be replaced by ordinary amphotericin B?
Clinically, sometimes. Conventional amphotericin B is cheaper but has greater renal and infusion toxicity. The products are not interchangeable on a milligram-per-milligram basis, and the choice depends on patient risk, monitoring capacity and local treatment guidelines.
Is AmBisome covered by a biosimilar pathway?
No. AmBisome is a liposomal small-molecule formulation, not a biologic. Competitors use the abbreviated new drug application pathway rather than the biosimilar pathway.
Why is generic AmBisome more difficult to develop than a standard generic injection?
The generic must reproduce the liposome's composition, size distribution, drug loading, free-drug content, stability and release characteristics. These attributes can affect safety, pharmacokinetics and tissue distribution.
Will AmBisome sales grow through 2030?
Total liposomal amphotericin B demand is likely to increase modestly, driven by invasive fungal infections, cryptococcal meningitis and visceral leishmaniasis. AmBisome's branded sales will face generic substitution and price pressure, so revenue growth is likely to trail category volume growth.
References
-
Jarvis, J. N., Lawrence, D. S., Meya, D. B., Kagimu, E., Kasibante, J., Musinguzi, P., et al. (2022). Single-dose liposomal amphotericin B treatment for cryptococcal meningitis. New England Journal of Medicine, 386(12), 1109-1120.
-
Molloy, S. F., Kanyama, C., Heyderman, R. S., Loyse, A., Kouanfack, C., Chanda, D., et al. (2018). Antifungal combinations for treatment of cryptococcal meningitis in Africa. New England Journal of Medicine, 378(11), 1004-1017.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: AmBisome, NDA 050740. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
World Health Organization. (2022). WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. World Health Organization.
